Latest filing published 21 Aug 2017 for Syros Pharmaceuticals, Inc..
Insider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +9.2%Entry US$158.00 · Close at T+365 US$172.60
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Flagship Ventures Fund IV, L.P.: trading record in brief
Flagship Ventures Fund IV, L.P. is a declared insider at 3 companies; the most frequent names are Sesen Bio, Inc., Syros Pharmaceuticals, Inc. and Editas Medicine, Inc. Between 8 February 2016 and 17 August 2017, the trades on record add up to 46 filings.
Both buying and selling appear: 2 purchases worth €4.5M, against 24 sales worth €3.2M. Purchases outweigh sales by €1.3M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
On 21 August 2017 came the latest disclosure, a transaction in Syros Pharmaceuticals, Inc. The latest purchase dates back some time: it was published 3,777 days ago, on 7 July 2016. Typically, a trade is published a median of 1 day after it takes place. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Flagship Ventures Fund IV, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,295,997 sharesCommon StockSEC:0001012975-17-000639:0
- 306,222 sharesCommon StockSEC:0001012975-17-000639:1
- 54,293 sharesCommon StockSEC:0001012975-17-000639:2
- 112,731 shares@ US$3.189.9% of flowCommon StockSEC:0001012975-16-001507:0
- 28,163 shares@ US$3.182.5% of flowCommon StockSEC:0001012975-16-001507:1
- 188,367 shares@ US$3.1716.5% of flowCommon StockSEC:0001012975-16-001507:2
- 47,090 shares@ US$3.174.1% of flowCommon StockSEC:0001012975-16-001507:3
- 12,482 shares@ US$3.161.1% of flowCommon StockSEC:0001012975-16-001507:4
- 3,118 shares@ US$3.160.3% of flowCommon StockSEC:0001012975-16-001507:5
- 41,178 shares@ US$3.103.5% of flowCommon StockSEC:0001012975-16-001507:6
- 10,293 shares@ US$3.100.9% of flowCommon StockSEC:0001012975-16-001507:7
- 7,761 shares@ US$3.310.7% of flowCommon StockSEC:0001012975-16-001505:0
- 1,939 shares@ US$3.310.2% of flowCommon StockSEC:0001012975-16-001505:1
- 43,139 shares@ US$3.394.1% of flowCommon StockSEC:0001012975-16-001505:2
- 10,778 shares@ US$3.391.0% of flowCommon StockSEC:0001012975-16-001505:3
- 258,214 shares@ US$3.7526.8% of flowCommon StockSEC:0001012975-16-001505:4
- 64,509 shares@ US$3.756.7% of flowCommon StockSEC:0001012975-16-001505:5
- 35,209 shares@ US$4.184.1% of flowCommon StockSEC:0001012975-16-001503:0
- 8,802 shares@ US$4.181.0% of flowCommon StockSEC:0001012975-16-001503:1
- 2,145 shares@ US$4.160.2% of flowCommon StockSEC:0001012975-16-001503:2
- 536 shares@ US$4.160.1% of flowCommon StockSEC:0001012975-16-001503:3
- 20,221 shares@ US$4.632.6% of flowCommon StockSEC:0001012975-16-001495:0
- 12,441 shares@ US$4.631.6% of flowCommon StockSEC:0001012975-16-001495:1
- 3,108 shares@ US$4.630.4% of flowCommon StockSEC:0001012975-16-001495:2
- 52,985 shares@ US$4.516.6% of flowCommon StockSEC:0001012975-16-001495:3
25 of 46 declarations
